Probiotics in women with breast cancer and chemotherapy

Study: Influence of orally administered probiotic Lactobacillus strains on vaginal microbiota in women with breast cancer during chemotherapy: A randomized placebo-controlled double-blinded pilot study.

Marschalek et al, Breast Care 2017

Background: Due to chemo- and oestrogen deprivation therapy, the genitourinary syndrome of postmenopausal women is common in breast cancer patients. We aimed to determine the effect of an orally administered Lactobacillus-preparation on the vaginal microbiota in breast cancer patients.

Patients and Methods

Postmenopausal breast cancer patients recei- ving chemotherapy, with vaginal atrophy and an intermediate vaginal microbiota (Nugent score 4-6) were either randomized to the interventi- on group, receiving probiotic capsules of four Lactobacillus species, or to the control group on placebo twice daily for two weeks. Consecutive vaginal swabs were taken at baseline, one day after the last capsule administration (follow-up 1), and after one week (follow-up 2) in 22 patients (11 vs. 11).


We observed a positive influence on the vaginal microbiota in 7/11 (63%) women in the interven- tion group, and 4/11 (36%) women in the control group. There was a shift of the Nugent score towards normal microbiota levels in the interven- tion group (-1.3 at follow-up 1, -0.45 at follow-up 2) and a significant deterioration of the Nugent score in the control group (+0.4 at follow-up 1, +2.5 at follow-up 2).


The orally administered Lactobacillus preparation has the potential to improve the vaginal microbiota of women with chemotherapy for primary breast cancer.


by Anthony P. Thomas PhD

Rationale and clinical research of vaginally-derived probiotic strains to support female urogenital tract health

This booklet reviews current understanding of the vaginal microbiota and its relationship to women’s health, as well as the rationale and clinical research to demonstrate the therapeutic potential of vaginally-derived probiotic strains L. crispatus LbV 88, L. jensenii LbV 116, L. gasseri LbV 150N, and L. rhamnosus LbV 96 to support vaginal microbial ecosystem balance. References to original research are provided for more in-depth review by medical and healthcare professionals.

The failure of most medical education programs to adequately teach future physicians about the human microbiota, its relationship to health, and appropriate clinical applications of specific, validated probiotic strains and multi-strain formulations for a given health condition, ultimately diminishes care for patients. It is critical that healthcare practitioners acknowledge the human microbiota and consider its role in health maintenance. Clinical research, dissemination of research results, and education will be key, as confusion about what constitutes a true probiotic-based intervention and misinformation are widespread.

Download Folder


• Lactobacillus crispatus LBV 88


DSM 22566

• Lactobacillus rhamnosus LBV 96


DSM 22560

• Lactobacillus jensenii LBV 116


DSM 22567

• Lactobacillus gasseri LBV 150N


DSM 22583

ASTARTE obtained the following patents and is deposited for further fillings in several countries.

European patent EP2509610 (DE, FR, IT, GB & CH)
US patent 8,846,027B2
Canadian patent 2,809,398
Eurasia patent No-024951 (Ukraine 115520)